Abstract:Photoreceptors and other cells of the retina consume large quantities of energy to efficiently convert light information into a neuronal signal understandable by the brain. The necessary energy is mainly provided by the oxygen-dependent generation of ATP in the numerous mitochondria of retinal cells. To secure the availability of sufficient oxygen for this process, the retina requires constant blood flow through the vasculature of the retina and the choroid. Inefficient supply of oxygen and nutrients, as it may occur in conditions of disturbed hemodynamics or vascular defects, results in tissue ischemia or hypoxia. This has profound consequences on retinal function and cell survival, requiring an adaptational response by cells to cope with the reduced oxygen tension. Central to this response are hypoxia inducible factors, transcription factors that accumulate under hypoxic conditions and drive the expression of a large variety of target genes involved in angiogenesis, cell survival and metabolism. Prominent among these factors are vascular endothelial growth factor and erythropoietin, which may contribute to normal angiogenesis during development, but may also cause neovascularization and vascular leakage under pathologically reduced oxygen levels. Since ischemia and hypoxia may have a role in various retinal diseases such as diabetic retinopathy and retinopathy of prematurity, studying the cellular and molecular response to reduced tissue oxygenation is of high relevance. In addition, the concept of preconditioning with ischemia or hypoxia demonstrates the capacity of the retina to activate endogenous survival mechanisms, which may protect cells against a following noxious insult. Part of these mechanisms is the local production of protective factors such as erythropoietin. Due to its plethora of effects in the retina including neuro- and vaso-protective activities, erythropoietin has gained strong interest as potential therapeutic factor for retinal degenerative diseases.

Addressing retinal hypoxia: pathophysiology, therapeutic innovations, and future prospects

Retinal ischemic diseases and promising therapeutic molecular targets

From oxygen to erythropoietin: relevance of hypoxia for retinal development, health and disease

Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Technologies

Novel Therapeutics for Diabetic Retinopathy and Diabetic Macular Edema: A Pathophysiologic Perspective

The evolving therapeutic landscape of diabetic retinopathy

The Different Facades of Retinal and Choroidal Endothelial Cells in Response to Hypoxia

Recent advances in the treatment and delivery system of diabetic retinopathy

Advances in Retinal Oximetry

Emerging Concepts in the Treatment of Diabetic Retinopathy

Recent Insights into Roles of Hypoxia-Inducible Factors in Retinal Diseases

Retinopathy of prematurity: inflammation, choroidal degeneration, and novel promising therapeutic strategies

Retinopathy of Prematurity—Targeting Hypoxic and Redox Signaling Pathways

Next generation therapeutics for retinal neurodegenerative diseases

The progress in understanding and treatment of diabetic retinopathy

Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade

Diabetic retinopathy: new therapeutic perspectives based on pathogenic mechanisms

Retinal Diseases: The Next Frontier in Pharmacodelivery

Hypoxia-inducible factor-1α: A promising therapeutic target for vasculopathy in diabetic retinopathy

Current research and future strategies for the management of vision-threatening diabetic retinopathy

Molecular Mechanisms of Diabetic Retinopathy, General Preventive Strategies, and Novel Therapeutic Targets